| 1 |
陈万青, 郑荣寿, 曾红梅, 等. 中国恶性肿瘤发病趋势分析和预测[J].中华预防医学杂志, 2012, 46(7): 581-586.
|
| 2 |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| 3 |
Mehan MR, Ayers D, Thirstrup D, et al. Protein signature of lung cancer tissues[J]. PLoS One, 2012, 7(4), e35157.
|
| 4 |
Luo G, Xiao Z, Long J, et al. CA125 is Superior to CA19-9 in predicting the resectability of pancreatic cancer[J]. J Gastrointest Surg,2013. [Epub ahead of print].
|
| 5 |
Hou SC, Xiao MB, Ni RZ, et al. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma[J].Oncol Lett, 2013, 6(4): 1152-1158.
|
| 6 |
Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum[J]. Science, 2011, 332(6030): 687-696.
|
| 7 |
Dittmar T, Heyder C, Gloria-Maercker E, et al. Adhesion molecules and chemok-ines: the navigation system for circulating tumor(stem) cells to metastasize in an organ-specific manner[J]. Clin Exp Metastasis, 2008, 25(1): 11-32.
|
| 8 |
Terstappen LW, Rao C, Gross S, et al. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast[J]. Int J Oncol, 2000, 17(3): 573-578.
|
| 9 |
Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer[J]. J Thorac Oncol, 2012,7(3): 512-519.
|
| 10 |
Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
|
| 11 |
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight[J]?Nat Rev Genet, 2008, 9(2): 102-114.
|
| 12 |
Di Leva G, Croce CM. Roles of small RNAs in tumor formation[J].Trends Mol Med, 2010, 16(6): 257-267.
|
| 13 |
Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2[J]. Proc Natl Acad Sci U S A, 2005,102(39): 13944-13949.
|
| 14 |
Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers[J].BMC Cancer, 2011, 11: 374.
|
| 15 |
Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(10): 1721-1726.
|
| 16 |
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review[J]. Lancet Oncol, 2013, 14(6): e218-228.
|
| 17 |
Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy[J]. J Immunother, 1997, 20(3): 165-177.
|
| 18 |
McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation[J]. J Immunol, 2004,172(7): 4275-4284.
|
| 19 |
Lebman DA, Edmiston JS. The role of TGF-beta in growth, diff erentiation, and, maturation of B lymphocytes[J]. Microbes Infect,1999, 1(15): 1297-1304.
|
| 20 |
Teicher BA. Transforming growth factor-beta and the immune response to malignant disease[J]. Clin Cancer Res, 2007, 13(21): 6247-6251.
|
| 21 |
Lin Y, Kikuchi S, Obata Y, et al. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer[J]. J Gastroenterol Hepatol, 2006, 21(2): 432-437.
|
| 22 |
Saito H, Tsujitani S, Oka S, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma[J]. Anticancer Res, 2000, 20(6B): 4489-4493.
|
| 23 |
Ivanovic V, Demajo M, Krtolica K, et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients[J]. Clin Chim Acta, 2006, 371(1-2): 191-193.
|
| 24 |
Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications[J]. World J Gastroenterol, 2005, 11(11): 1639-1643.
|
| 25 |
Chen CJ, Sung WW, Su TC, et al. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients[J]. Clin Chim Acta, 2012, 415: 25-30.
|
| 26 |
Nacinovic-Duletic A, Stifter S, Dvornik S, et al. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma[J]. Int J Lab Hematol, 2008, 30(3): 230-239.
|
| 27 |
Shibata M, Nezu T, Kanou H, et al. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer[J]. J Clin Gastroenterol,2002, 34(4): 416-420.
|
| 28 |
Ciszak L, Kosmaczewska A, Werynska B, et al. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer[J]. Oncol Rep, 2009, 21(1): 173-184.
|
| 29 |
Okamoto M, Azuma K, Hoshino T, et al. Correlation of decreased survival and IL-18 in bone metastasis[J]. Intern Med, 2009, 48(10): 763-773.
|
| 30 |
Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients[J]. Curr Pharm Biotechnol, 2011, 12(12): 2176-2189.
|
| 31 |
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial[J]. Lancet, 2008, 372(9652): 1809-1818.
|
| 32 |
Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, doubleblind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961.
|
| 33 |
Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer[J]. J clin Oncol, 2009, 27(16): 2653-2659
|
| 34 |
Taly V, Pekin D, Benhaim L, et al. Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients[J]. Clin Chem, 2013. [Epub ahead of print].
|
| 35 |
Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer[J]. J Clin Oncol, 2010, 28(23): 4985-4995.
|
| 36 |
Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospectivstudy[J]. Science,1998, 279(5350): 563-566.
|
| 37 |
Chan JM, Stampfer MJ, Ma J, et al. Insulinlike growth factor-I (IGF-I)and IGF binding protein-3 as predictors of advanced-stage prostate cancer[J]. J Natl Cancer Inst, 2002, 94(14): 1099-1106.
|
| 38 |
Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer[J]. Lancet, 1998, 351(9113): 1393-1396.
|
| 39 |
Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3[J]. J Natl Cancer Inst, 1999, 91(7): 620-625.
|
| 40 |
Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer[J]. Front Biosci, 2008, 13: 3906-3912.
|
| 41 |
Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulinlike growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer[J]. Cancer Res, 2008,68(5): 1538-1545.
|
| 42 |
Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity[J]. J Biol Chem, 2005, 280(20): 19665-19672.
|
| 43 |
Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)[J]. J Natl Cancer Inst, 2001, 93(24): 1852-1857.
|
| 44 |
Ueda S, Hatsuse K, Tsuda H, et al. Potential crosstalk between insulinlike growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer[J]. Mod Pathol,2006, 19(6): 788-796.
|
| 45 |
Assy N, Pruzansky Y, Gaitini D, et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction[J]. J Hepatol, 2008, 49(1): 34-42.
|
| 46 |
Wu YL, Ye J, Zhang S, et al. Clinical significance of serum IGF-I,IGF-II and IGFBP-3 in liver cirrhosis[J]. World J Gastroenterol, 2004,10(18): 2740-2743.
|
| 47 |
Cho EJ, Lee JH, Yoo JJ, et al. Serum insulin-like growth factor-I level Is an independent predictor of recurrence and survival in early hepatocellular carcinoma: A prospective cohort study[J]. Clin Cancer Res, 2013, 19(15): 4218-4227.
|
| 48 |
Kamiya K, Watanabe M. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer[J]. Respirology, 2011, 16(6): 976-982.
|
| 49 |
Niimi R, Matsumine A, Iino T, et al. Soluble neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors[J]. BMC Cancer, 2013, 13(1): 309.
|